2025年6月20日 周五
首页 > 按月查看>2023年第5月 >456-460. DOI:10.20039/j.cnki.1007 3949.2023.05.013
PDF 导出
阿克曼氏菌与动脉粥样硬化关系的研究进展
作者:
作者单位:

(1.哈尔滨医科大学附属第二医院心内科,黑龙江省哈尔滨市 150001;2.心肌缺血教育部重点实验室, 黑龙江省哈尔滨市 150001;3.南华大学附属第一医院心内科,湖南省衡阳市 421001)

作者简介:

赵鹏,硕士研究生,研究方向为心血管疾病的预防和治疗,E-mail:drzhaopeng2020@163.com。通信作者刘新新,博士,副主任医师,硕士研究生导师,研究方向为心血管疾病的预防和治疗,E-mail:lxx_hmu@vip.126.com。

基金项目:

心肌缺血教育部重点实验室开放课题(KF202011)


Research progress in the relationship between Akkermansia and atherosclerosis
Author:
Affiliation:

1.Department of Cardiology, the 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China;2.The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, Heilongjiang 150001, China;3.Department of Cardiology, the 1st Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China)

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献
    • |
  • 相似文献
    • | |
    摘要:

    动脉粥样硬化(As)是一种复杂的慢性炎症性疾病,是导致缺血性心脏病和中风在内的心血管疾病(CVD)的主要病因,在世界范围内造成很高的发病率和死亡率。近年来,肠道菌群在As中的作用受到广泛关注。而阿克曼氏菌作为一种重要的抗As作用的有益菌却少有综述。深入探讨As发病机制及潜在治疗方法是当前医学发展的焦点。因此,文章就阿克曼氏菌如何发挥抗As作用及与抗As药物之间的关系予以综述。

    Abstract:

    Atherosclerosis (As), a complex chronic inflammatory disease, that is a major cause of cardiovascular diseases (CVD) including ischemic heart disease and stroke, causing high morbidity and mortality worldwide. In recent years, the role of gut microbiota in atherosclerosis has received extensive attention. However, as an important anti-atherosclerosis beneficial bacteria, Akkermansia is rarely reviewed. In-depth study of the pathogenesis and potential treatment of atherosclerosis is the focus of current medical development. Therefore, this article reviews how Akkermansia exerts its anti-atherosclerotic effect and its relationship with anti-atherosclerotic drugs.

    参考文献
    [1] LIBBY P, BURING J E, BADIMON L, et al.Atherosclerosis.Nat Rev Dis Primers, 9,5(1):56.
    [2] BRANDSMA E, KLOOSTERHUIS N J, KOSTER M, et al.A proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis.Circ Res, 9,4(1):94-100.
    [3] DOMINGUEZ-BELLO M G, GODOY-VITORINO F, KNIGHT R, et al.Role of the microbiome in human development.Gut, 9,8(6):1108-1114.
    [4] QIN J, LI R, RAES J, et al.A human gut microbial gene catalogue established by metagenomic sequencing.Nature, 0,4(7285):59-65.
    [5] MILANI C, DURANTI S, BOTTACINI F, et al.The first microbial colonizers of the human gut:composition, activities, and health implications of the infant gut microbiota.Microbiol Mol Biol Rev, 7,1(4):e00036-17.
    [6] DERRIEN M, VAUGHAN E E, PLUGGE C M, et al.Akkermansia muciniphila gen.nov., sp.nov., a human intestinal mucin-degrading bacterium.Int J Syst Evol Microbiol, 4,4(Pt 5):1469-1476.
    [7] DERRIEN M, COLLADO M C, BEN-AMOR K, et al.The mucin degrader akkermansia muciniphila is an abundant resident of the human intestinal tract.Appl Environ Microbiol, 8,4(5):1646-1648.
    [8] JAYACHANDRAN M, CHUNG S S M, XU B J.A critical review of the relationship between dietary components, the gut microbe Akkermansia muciniphila, and human health.Crit Rev Food Sci Nutr, 0,0(13):2265-2276.
    [9] NAITO Y, UCHIYAMA K, TAKAGI T.A next-generation beneficial microbe:Akkermansia muciniphila.J Clin Biochem Nutr, 8,3(1):33-35.
    [10] KALIA VC, GONG C, SHANMUGAM R, et al.The emerging biotherapeutic agent:Akkermansia.Indian J Microbiol, 2,2(1):1-10.
    [11] RODRIGUES V F, ELIAS-OLIVEIRA J, PEREIRA I S, et al.Akkermansia muciniphila and gut immune system:a good friendship that attenuates inflammatory bowel disease, obesity, and diabetes.Front Immunol, 2,3:934695.
    [12] LEWIS C V, WR T.Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease.Am J Physiol Heart Circ Physiol, 0,9(6):1227-1233.
    [13] BANSIL R, TURNER B S.The biology of mucus:composition, synthesis and organization.Adv Drug Deliv Rev, 8,4:3-15.
    [14] REUNANEN J, KAINULAINEN V, HUUSKONEN L, et al.Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer.Appl Environ Microbiol, 5,1(11):3655-3662.
    [15] COLLADO M C, DERRIEN M, ISOLAURI E, et al.Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly.Appl Environ Microbiol, 7,3(23):7767-7770.
    [16] PLOVIER H, EVERARD A, DRUART C, et al.A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice.Nat Med, 7,3(1):107-113.
    [17] LI J, LIN S, VANHOUTTE P M, et al.Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in ApoE－/－ Mice.Circulation, 6,3(24):2434-2446.
    [18] ZHU Y, LI T H, DIN A U, et al.Beneficial effects of enterococcus faecalis in hypercholesterolemic mice on cholesterol transportation and gut microbiota.Appl Microbiol Biotechnol, 9,3(7):3181-3191.
    [19] KATIRAEI S, DE VRIES M R, COSTAIN A H, et al.Akkermansia muciniphila exerts lipid-lowering and immunomodulatory effects without affecting neointima formation in hyperlipidemic ApoE*3-leiden.CETP mice.Mol Nutr Food Res, 0,4(15):e1900732.
    [20] BAVINENI M, WASSENAAR T M, AGNIHOTRI K, et al.Mechanisms linking preterm birth to onset of cardiovascular disease later in adulthood.Eur Heart J, 9,0(14):1107-1112.
    [21] BAE M, CASSILLY C D, LIU A A, et al.Akkermansia muciniphila phospholipid induces homeostatic immune responses.Nature, 2,8(7921):168-173.
    [22] LU Y C, YEH W C, OHASHI P S.LPS/TLR4 signal transduction pathway.Cytokine, 8,2(2):145-151.
    [23] 赵鹏, 刘新新, 田进伟.肠道菌群代谢物与心血管疾病关系的研究进展.中国动脉硬化杂志, 1,9(12):1094-1098.ZHAO P, LIU X X, TIAN J W.Research progress in the relationship between intestinal flora metabolites and cardio-vascular disease.Chin J Arterioscler, 1,9(12):1094-1098.
    [24] KASAHARA K, REY F E.The emerging role of gut microbial metabolism on cardiovascular disease.Curr Opin Microbiol, 9,0:64-70.
    [25] GREGORY J C, BUFFA J A, ORG E, et al.Transmission of atherosclerosis susceptibility with gut microbial transplantation.J Biol Chem, 5,0(9):5647-5660.
    [26] CHEN M L, ZHU X H, RAN L, et al.Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway.J Am Heart Assoc, 7,6(9):e006347.
    [27] CHEN M L, YI L, ZHANG Y, et al.Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota.mBio, 6,7(2):e02210-e02215.
    [28] WANG Z N, HAZEN J, JIA X, et al.The nutritional supplement L-alpha glycerylphosphorylcholine promotes atherosclerosis.Int J Mol Sci, 1,2(24):13477.
    [29] SONG D Y, HAO J Y, FAN D M.Biological properties and clinical applications of berberine.Front Med, 0,4(5):564-582.
    [30] DONG C R, YU J Q, YANG Y N, et al.Berberine, a potential prebiotic to indirectly promote Akkermansia growth through stimulating gut mucin secretion.Biomed Pharmacother, 1,9:111595.
    [31] ZHU L, ZHANG D Y, ZHU H, et al.Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in ApoE－/－ mice.Atherosclerosis, 8,8:117-126.
    [32] CHENG T T, LI C K, SHEN L Y, et al.The intestinal effect of atorvastatin:Akkermansia muciniphila and barrier function.Front Microbiol, 1,2:797062.
    [33] WANG L J, ZHOU W W, GUO M Y, et al.The gut microbiota is associated with clinical response to statin treatment in patients with coronary artery disease.Atherosclerosis, 1,5:16-23.
    [34] KHAN T J, AHMED Y M, ZAMZAMI M A, et al.Atorvastatin treatment modulates the gut microbiota of the hypercholesterolemic patients.OMICS, 8,2(2):154-163.
    [35] SU C, LI X, YANG Y, et al.Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality.Nutr Diabetes, 1,1(1):27.
    [36] TAN J, MCKENZIE C, POTAMITIS M, et al.The role of short-chain fatty acids in health and disease.Adv Immunol, 4,1:91-119.
    [37] DE LA CUESTA-ZULUAGA J, MUELLER N T, CORRALES-AGUDELO V, et al.Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut.Diabetes Care, 7,0(1):54-62.
    [38] YAN N, WANG L J, LI Y W, et al.Metformin intervention ameliorates As in ApoE－/－ mice through restoring gut dysbiosis and anti-inflammation.PLoS One, 1,6(7):e0254321.
    [39] LIN K Y, WANG X D, LI J, et al.Anti-atherosclerotic effects of geraniin through the gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway in mice.Phytomedicine, 2,1:154104.
    [40] CHEN P Y, LI S M, KOH Y C, et al.Oolong tea extract and citrus peel polymethoxyflavones reduce transformation of L-carnitine to trimethylamine-N-Oxide and decrease vascular inflammation in L-carnitine feeding mice.J Agric Food Chem, 9,7(28):7869-7879.
    [41] WANG X, LI X, DONG Y.Vitamin D decreases plasma trimethylamine-N-oxide level in mice by regulating gut microbiota.Biomed Res Int, 0,0:9896743.
    [42] SHI N, ZHANG S Y, SILVERMAN G, et al.Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis.Animal Model Exp Med, 9,2(2):98-106.
    引证文献
引用本文

赵鹏,郑玉琪,田进伟,刘新新.阿克曼氏菌与动脉粥样硬化关系的研究进展[J].中国动脉硬化杂志,2023,31(5):456~460.

复制
分享
文章指标
  • 点击次数:289
  • 下载次数: 846
历史
  • 收稿日期:2022-08-31
  • 最后修改日期:2022-10-29
  • 在线发布日期: 2023-05-19

您是本站第 4895106 访问者

邮编：421001 传真：0734-8160523

电话：0734-8160765 E-mail：dmzzbjb@163.net

中国动脉硬化杂志 ® 2025 网站版权所有